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Purpose: To evaluate the anatomy of the substantia nigra (SN) in 
healthy subjects by performing 7-T magnetic resonance 
(MR) imaging of the SN, and to prospectively define the 
accuracy of 7-T MR imaging in distinguishing Parkinson 




The 7-T MR imaging protocol was approved by the Ital-
ian Ministry of Health and by the local competent ethics 
committee. SN anatomy was described ex vivo on a gross 
brain specimen by using highly resolved proton-density 
(spin-echo proton density) and gradient-recalled-echo 
(GRE) images, and in vivo in eight healthy subjects (mean 
age, 40.1 years) by using GRE three-dimensional multi-
echo susceptibility-weighted images. After training on 
appearance of SN in eight healthy subjects, the SN anat-
omy was evaluated twice by two blinded observers in 13 
healthy subjects (mean age, 54.7 years) and in 17 PD pa-
tients (mean age, 56.9 years). Deviations from normal SN 
appearance were described and indicated as abnormal, 
and both diagnostic accuracy and intra- and interobserver 
agreement for diagnosis of PD with 7-T MR imaging were 
calculated.
Results: Three-dimensional multiecho susceptibility-weighted 7-T 
MR imaging reveals a three-layered organization of the SN 
allowing readers to distinguish pars compacta ventralis and 
dorsalis from pars reticulata. The abnormal architecture of 
the SN allowed a discrimination between PD patients and 
healthy subjects with sensitivity and specificity of 100% 
and 96.2% (range, 92.3%–100%), respectively. Intraob-
server agreement (k = 1) and interobserver agreement 
(k = 0.932) were excellent.
Conclusion: MR imaging at 7-T allows a precise characterization of 
the SN and visualization of its inner organization. Three-
dimensional multiecho susceptibility-weighted images 
can be used to accurately differentiate healthy subjects 
from PD patients, which provides a novel diagnostic 
opportunity.
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vivo by using a 7-T MR imager (MR950; 
GE Healthcare, Milwaukee, Wis) 
equipped with a two-channel transmis-
sion and 32-channel receiver head coil 
(Nova Medical, Wilmington, Mass).
For ex vivo examination of the SN, a 
gross specimen from a human cadaver 
of a 67-year-old woman was used. The 
subject was selected because she had 
unremarkable neurologic and psychiat-
ric history, she underwent autopsy for 
death of cardiac origin, and her central 
nervous system was normal at patho-
logic examination. The brain specimen, 
which had been fixed in a 10% aqueous 
solution of formaldehyde, was removed 
from formalin and placed in a perfluo-
ropolyether suspension (Fomblin; Sol-
vay-Solexis, Milan, Italy) before it was 
imaged.
Ex vivo MR imaging acquisitions 
consisted of proton density–weighted 
spin-echo two-dimensional GRE and 
three-dimensional multiecho suscepti-
bility-weighted (SWAN; GE Healthcare) 
targeted images of the midbrain, ac-
quired in the axial-oblique plane per-
pendicular to the floor of the fourth 
ventricle and in the coronal-oblique 
plane parallel to the floor of the fourth 
ventricle. The following parameters 
were used for spin-echo proton density: 
repetition time msec/echo time msec, 
1200/20; number of signals acquired, 
two; flip angle, 90°; section thickness, 
Conventional and advanced MR 
techniques at standard field strength 
have limitations in the evaluation of 
SN because both spatial resolution and 
contrast-to-noise ratio are insufficient 
to measure the inner structure of SN 
and the modest quantitative differences 
induced by the loss of dopaminergic 
neurons.
MR imaging at 7 T has great poten-
tial to provide new insight into neuro-
anatomy and a wide range of neuropath-
ologic conditions, and could provide new 
scenarios in the clinical MR application 
of structural imaging (18). MR imaging 
at 7 T could be used to increase the spa-
tial resolution by exploiting the higher 
signal-to-noise ratio to improve the qual-
ity of targeted MR images that focus on 
the brain structures involved in a spe-
cific pathologic process (19). In particu-
lar, the use of GRE sequences may im-
prove the characterization of nuclei that 
contain iron and neuromelanin involved 
in PD (20–23).
We performed an exploratory study 
to evaluate the anatomy of the SN in 
healthy subjects by using targeted 7-T 
MR imaging of the SN, and we prospec-
tively defined the accuracy of 7-T MR 
imaging to distinguish PD patients from 
healthy subjects on an individual basis.
Materials and Methods
All patients and control subjects gave 
their written informed consent to the 
enrollment and diagnostic procedures 
on the basis of the adhesion to an ex-
perimental protocol that was approved 
and funded by Italian Ministry of Health 
and cofunded by the Health Service of 
Tuscany. The study was approved by the 
local ethics committee. MR images were 
obtained from April 2012 to April 2013.
Normal 7-T MR Imaging Anatomy of the SN
The normal 7-T MR imaging anatomy of 
SN was investigated both ex vivo and in 
Parkinson disease (PD) is a com-mon neurodegenerative disease characterized by disabling motor 
and nonmotor symptoms. The patho-
logic correlate of nigrostriatal dopami-
nergic degeneration is the neuronal loss 
in substantia nigra (SN) pars compacta, 
particularly in the ventrolateral tier of 
neurons (1).
Standard magnetic resonance 
(MR) imaging techniques have a mar-
ginal role in the diagnosis and fol-
low-up of PD (2,3), and there is no es-
tablished MR imaging marker for the 
diagnosis of PD. T1- and T2-weight-
ed, spin-echo, gradient-recalled-echo 
(GRE) sequences and segmented 
inversion-recovery ratio imaging (4) 
fail to visualize in detail the normal 
anatomy of the SN, and they are not 
sufficiently sensitive to the damage 
caused by nigrostriatal degeneration 
in PD (5,6). These techniques do not 
distinguish SN pars compacta from 
the SN pars reticulata, and therefore 
correlation with clinical indices of 
disease severity is difficult, and their 
employment is of little use in clinical 
practice (6).
SN-derived biomarkers (eg, relax-
ometry [7–10], diffusion tensor imag-
ing [11,12], and neuromelanin imaging 
[13–17]) can be obtained in PD, but 
they are being evaluated because of in-
terstudy inconsistencies, and they have 
a limited role in a single-subject evalua-
tion. Currently, none of them is applied 
in clinical practice (2).
Implication for Patient Care
 n The identification of a radiologic 
marker of the altered SN by using 
7-T MR imaging allows an imag-
ing-based early diagnosis of PD.
Advances in Knowledge
 n MR imaging at 7 T reveals a 
three-layered organization of the 
substantia nigra (SN) in both in 
vivo and ex vivo brainstem.
 n MR imaging at 7 T demonstrates 
in vivo a simple radiologic sign 
that shows the loss of the inter-
mediate hyperintense SN compo-
nent that correctly classifies 
patients with Parkinson disease 
(PD) with a sensitivity of 100% 
and specificity of 96.2% (range 
92.3%-100%) with excellent 
intraobserver (k = 1) and inter-
observer (k = 0.932) agreement.
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years]; four women [mean age, 55.2 
years; age range, 47–66 years] and nine 
men [mean age, 54.4 years; age range, 
41–64 years]) were enrolled to assess 
the accuracy of 7-T MR imaging of SN 
for differentiating PD patients from 
controls. They had no personal or fam-
ily history of psychiatric and neurologic 
disorders, and their general and neuro-
logic examinations were unremarkable.
Demographic and clinical data for 
healthy subjects and patients are shown 
in Table 1 (28,29).
The MR imaging protocol for the 
healthy subjects and PD patients in-
cluded several different multiparamet-
ric acquisitions (18). This contribution 
focuses on acquisitions obtained by 
using three-dimensional multiecho sus-
ceptibility-weighted sequences with the 
same parameters evaluation of normal 
SN anatomy.
After a training on the normal ap-
pearance of SN at 7-T MR imaging, 
two neuroradiologists (M.C. and I.P.) 
were invited to describe as abnormal 
any deviation from normal anatomy 
in three-dimensional GRE (ie, three-
dimensional multiecho susceptibility-
weighted imaging)-targeted images 
of SN acquired in PD patients and 
healthy subjects. SN-targeted three-
dimensional multiecho susceptibility-
weighted images of PD and healthy 
subjects were entered into a database 
and presented in a blinded and ran-
domized manner, which ensured that 
the readers were unaware of the clin-
ical diagnosis. Readers were asked to 
give an MR imaging diagnosis accord-
ing to the abnormal appearance of the 
SN, and the images of each subject 
were presented twice after 7 days to 
calculate intra- and interrater reliabil-
ity. Subjects were considered to have 
been affected by PD when at least one 
level (out of three) of one side of the 
SN was abnormal. Intra- and interob-
server reliability of responses from 
each reader were cross-tabulated to 
enable the calculation of agreement 
and the Cohen k statistic (30). Demo-
graphic data of healthy subjects and 
PD patients were compared by Student 
t test and x2 test. Sensitivity, specific-
ity, and diagnostic accuracy regarding 
levels of the midbrain along the ros-
trocaudal axis: (a) the inferior third of 
the red nuclei (ie, level I); (b) the supe-
rior cerebellar pedicle decussation (ie, 
level II); and (c) the inferior colliculi 
(ie, level III) (Fig 1).
According to the exploratory nature 
of the work, the normal anatomy of SN 
at 7 T was assessed by comparing 7-T 
MR images with neuroanatomic atlases 
images (24–26).
Pathologic Changes of the SN in PD 
Patients at 7-T MR Imaging
Nineteen patients with PD (according 
to clinical criteria for probable PD per 
the Parkinson’s UK Brain Bank [27]) 
were consecutively enrolled from a ter-
tiary movement disorder center.
Atypical PD disorders (ie, multiple 
system atrophy, progressive supranu-
clear palsy, corticobasal degeneration, 
dementia, and other neurologic or 
major medical conditions) were con-
sidered to be criteria for exclusion. All 
patients underwent 1.5-T MR imaging 
to exclude radiologic signs of atypical 
PD, neoplastic lesions, hydrocephalus, 
or extensive vascular damage. In newly 
diagnosed PD patients, levodopa chal-
lenge was performed to evaluate acute 
dopaminergic treatment efficacy, and 
only patients with a consistent (.30%) 
improvement in the tapping test were 
eligible. A 123 iodine fluoropropyl car-
bomethoxy iodophenyl tropane sin-
gle-photon-emission computed tomo-
graphic scan was performed to confirm 
nigrostriatal degeneration. Thirteen PD 
patients were on anti-PD medication at 
the time of 7-T MR imaging.
Two patients were excluded because 
their images were severely affected by 
head motion artifacts. Right-handed 
PD patients were included in the final 
analysis (17 patients [mean age, 56.9 
years; age range, 38–70 years]; nine 
women [mean age, 52.2 years; age 
range, 38–64 years] and eight men 
[mean age, 61.1 years; age range, 46–
70 years]).
Aged-matched (64 years [toler-
ated difference for age among PD and 
healthy subjects]) right-handed healthy 
subjects (13 healthy subjects [mean 
age, 54.7 years; age range, 41–66 
1 mm; spacing, 1.5 mm; receiver band-
width, 65.1 kHz; field of view, 10 3 10 
cm; in-plane resolution, 190 mm. The 
following parameters were used for two-
dimensional GRE: 240/12.7; two signals 
acquired; flip angle, 15°; section thick-
ness, 1 mm; spacing, 1.5 mm; receiver 
bandwidth, 61.0 kHz; field of view, 10 
3 10 cm; in-plane resolution, 190 mm. 
The following parameters were used 
for the three-dimensional multiecho 
susceptibility-weighted sequence: 7.5, 
15.2, 22.8, 30.3, 37.8/56.5; number 
of signals acquired, one; section thick-
ness, 1.0 mm; 40 sections; field of view, 
16 3 16 cm; receiver bandwidth, 50 
kHz; in-plane resolution, 312 mm.
Right-handed healthy subjects (eight 
healthy subjects [mean age, 40.1 years; 
age range, 25–62 years]; five women 
[mean age, 44.4 years; age range, 39–
62 years] and three men [mean age, 33 
years; age range, 25–40 years]) were 
consecutively enrolled. We assessed the 
7-T MR images of their SNs. They had 
no personal or family history of psy-
chiatric and neurologic disorders, and 
their general and neurologic examina-
tions were unremarkable.
In vivo acquisitions were per-
formed by using a three-dimensional 
multiecho susceptibility-weighted 
sequence (5.57, 10.7, 15.84, 20.97, 
26.1, 31.23, 36.36, 41.5/55.7; number 
of signals acquired, 0.67; section 
thickness, 1.2 mm; 18 sections; field of 
view, 16 3 16 cm; in-plane resolution, 
312 mm; receiver bandwidth, 67 kHz), 
which targeted the midbrain, was ori-
ented in the plane perpendicular to the 
fourth ventricle floor, and covered 21.6 
mm above the pontomesencephalic 
junction. The imager reconstructed 
the final output image into a 512 3 512 
3 18 matrix by averaging the images 
obtained for each single echo. The to-
tal acquisition time was 242 seconds.
Ex vivo and in vivo 7-T MR target-
ed images of the midbrain were evalu-
ated by consensus by two experienced 
neuroradiologists (M.C. and I.P., 21 
and 8 years of experience in MR imag-
ing evaluation, respectively) to define 
the external borders and internal or-
ganization of SN. The two observers 
evaluated SN at the following three 
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clinical diagnosis were calculated by 
using statistical software (SPSS v.18; 
SPSS, Chicago, Ill).
Results
Normal 7-T MR Anatomy of the SN
In vivo three-dimensional multiecho 
susceptibility-weighted images show 
the SN as an oval flattened structure 
that is limited ventrally by the cerebral 
peduncles and dorsally by the superior 
cerebellar pedicle decussation and the 
red nuclei. A homogeneous hypoin-
tense region at the upper level (level I) 
was observed medially by both readers, 
Figure 1
Figure 1: Top row: 7-T three-dimensional multiecho susceptibility-weighted in vivo images of SN in healthy 64-year-old man, located between the crus cerebri 
(a) and the red nucleus. Axial sections perpendicular to the floor of fourth ventricle are obtained at level of the inferior third of the red nucleus (level I), at the level of 
decussation of superior cerebellar peduncles (e) (level II), and at the level of the inferior colliculi (level III). At level I, SN appears as homogeneous hypointense structure 
in the medial part of the cerebral peduncle, and is laterally constituted by a hyperintense oval area between two hypointense layers (c1). At level II, a trilaminar 
organization of the SN with a central hyperintense layer (b) between two hypointense tiers (c and d) is detectable. At level III, the dorsal hypointense lamina could be 
detected as a small residual lateral hypointense area, while the hyperintense layer fades into the isointense cerebral peduncle. Bottom row: 7-T three-dimensional 
multiecho susceptibility-weighted in vivo images of the SN in PD patients. The loss of normal anatomy of the SN in a 61-year-old man with PD is characterized by 
the disappearance of the oval-shape bright spot in the lateral part of the SN at level I and by the loss of the hyperintense intermediate layer of the SN at level II. HC = 
healthy subject.
Table 1
Demographic and Clinical Data of Healthy Subjects and PD Subjects
Parameter Healthy Subjects (n = 13) Mean PD Patients 6 SD; range (n = 17)
No. of men 9 9
No. of women 4 8
Disease duration (mo) NA 27.2 6 23.0; 6–96
Hoehn and Yahr NA 1.7 6 0.4; 1–2
UPDRS level II NA 6.9 6 3.7; 2–13
UPDRS level III NA 17.8 6 9.0; 9–37
MMSE 30 29.0 6 0.3; 29–30
Note.—There were 13 healthy subjects and 17 PD patients. Hoehn and Yahr disease staging (28). MMSE = Mini–Mental State 
Examination, SD = standard deviation, UPDRS = Unified Parkinson’s Disease Rating Scale. 
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judgment of both readers for each item 
was reported in Table 2.
For reader 1, abnormal SN in three-
dimensional multiecho susceptibility-
weighted images was present in 17 of 17 
PD patients, while SN was normal in 13 
of 13 healthy subjects. Sensitivity, speci-
ficity, positive predictive value, and neg-
ative predictive value for the diagnosis of 
PD were each 100%.
For reader 2, SN was judged to be 
abnormal in 17 of 17 PD patients and 
normal in 12 of 13 healthy subjects. 
Sensitivity, specificity, positive predictive 
value, and negative predictive value for 
the diagnosis of PD were 100%, 92.3%, 
94.4%, and 100%, respectively. k values 
were excellent for both intraobserver 
agreement (k = 1) and interobserver 
agreement (k = 0.932).
Discussion
The main results of the our study are 
the demonstration of the capability of 
7-T MR imaging to depict the borders 
of the SN and its inner organization, 
and to reveal simple radiologic signs 
Such complex organization of the 
SN is detectable in even higher detail 
on ex vivo images (Fig 2). Both readers 
described a ventral low-signal-intensity 
layer, an intermediate high-signal-in-
tensity tier and a dorsal low-signal-in-
tensity tier, both on spin-echo proton 
density (Fig 2, right) and GRE (Fig 2, 
left) images. Unlike on GRE images, 
the ventral low-signal-intensity layer on 
spin-echo proton density images (Fig 
2, right) does not extend to the medial 
part of the crus cerebri that is clearly 
constituted by white matter fibers.
Pathologic Changes of SN in PD Patients 
at 7-T MR Imaging
After training on the appearance of SN 
in healthy subjects, the two readers 
consensually defined the SN as ab-
normal if at least one of the following 
aspects was observed (Fig 1): At the 
lower level (level III), hypointensity was 
represented both in the medial and lat-
eral part, and in the middle (level II) 
and upper levels (level I) the three lay-
ered organization and the hyperintense 
lateral spot were not detectable. The 
while a small hyperintense area that re-
sembled a bright spot was observed lat-
erally between two hypointense layers. 
At the longitudinal midlevel (level II), a 
trilaminar organization was character-
ized by a central hyperintense layer be-
tween two hypointense laminae. At the 
lower level (level III), the dorsal hypoin-
tense lamina was detected as a small 
residual lateral hypointense area, while 
the hyperintense layer faded into the 
isointense cerebral peduncle.
In summary, the two readers agreed 
in their description of three tiers of 
signal intensity along the dorsoventrad 
axis of the midbrain. From back to front, 
they observed a thin low signal band, fol-
lowed by a high signal structure, which 
appeared oval at the upper level (bright 
spot) and laminar at the midlevel (three 
layers), and, anteriorly, a large band of 
signal hypointensity extending antero-
medially into the crus cerebri. Both the 
ventral and dorsal hypointense layers 
extended along the caudo-rostral and 
lateromedial direction, and fused later-
ally at the lower level and medially at the 
upper level (Fig 1).
Figure 2
Figure 2: Images show axial spin-echo proton density (on the right) and GRE (on the left) of the SN at level I of an ex vivo brain 
sample in a 67-year-old woman. There is a triple-layered organization of the SN comparable to that showed in the in vivo images. 
Ventrally a low-signal-intensity layer (b) is attributable to the pars reticulata of the SN. In the middle part of the SN, a hyperintense 
band (c) corresponds to the ventral component of the pars compacta of the SN. The lateral part of this layer shows a high-signal-
intensity spot (c1) corresponding to the oval shape hyperintensity of the in vivo three-dimensional multiecho susceptibility-weighted 
images that resemble the nigrosome formation. The dorsal hypointense layer visible on both spin-echo and GRE images (d) is re-
ferred to the dorsal component of the pars compacta of the SN. a = crus cerebri, e = brachjum conjunctivum, f = medial lemniscus, 
g = lateral lemniscus, h = central tegmental tract.
836 radiology.rsna.org n Radiology: Volume 271: Number 3—June 2014
NEURORADIOLOGY: MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease Cosottini et al
Moreover, the loss of the so-called 
bright spot in the lateral component of 
the SN pars compacta ventralis in PD 
corresponds to a recently described 
(23) disappearance of a pocket-like 
region inside the lateral portion of the 
SN that was revealed by a complex 
surface analysis of the SN obtained at 
7 T. In that study (23), Kwon et al 
reported that PD patients have a vol-
ume expansion of the SN, measured 
by using susceptibility-weighted imag-
ing, and that the larger extent of the 
signal hypointensity in patients fills in 
the inflected pocket-like region of the 
lateral portion of SN that is usually 
visible in healthy subjects.
Previous 7-T MR imaging studies 
in patients with PD showed an in-
creasing amount of undulation in the 
anterior profile of the SN by using 
GRE images (20). However, this sign 
appears not to be suitable as a simple 
method for clinical use because the 
SN alteration in PD does not mainly 
involve its reticular component, and 
because the anterior border of SN 
pars reticulata in GRE images cannot 
be precisely identified since it extends 
beyond its anterior anatomic land-
mark (6,38).
From a radiologic perspective, to 
our knowledge this is the first demon-
stration of a robust MR imaging sign 
that promptly identifies PD patients 
with respect to controls. Consider-
ing the limited cooperativeness of PD 
patients, the possibility of reaching a 
diagnostic result by using a short (242 
seconds), single, targeted, three-di-
mensional, multiecho, susceptibility-
weighted sequence with an excel-
lent interobserver agreement is an 
important goal of 7-T MR imaging. 
Because at present 7-T MR imaging 
systems are authorized exclusively for 
research purpose and not for clinical 
use, the demonstration of their clin-
ical usefulness and their safety will 
be the conditions required for their 
acceptance in the medical community.
The main limitation of our study 
is that the inner architecture of the 
SN, identifiable by using 7-T MR im-
aging, is not confirmed with immu-
nohistochemical methods, and the 
midbrain in healthy subjects. We be-
lieve that the anterior hypointense tier 
corresponds to the pars reticulata of 
the SN, and the posterior and inter-
mediate tiers correspond respectively 
to the dorsal and the ventral compo-
nents of the SN pars compacta, which 
is more cellulated and contains dopa-
minergic neurons (35). In particular, 
nigrosome 1 is the largest and highly 
dense cluster of calbindin-negative 
neurons within the SN pars compacta 
ventralis (33) and is located in the in-
termediate and lateral portion of SN 
pars compacta ventralis, which shows 
the distribution of the round hyper-
intense area observed in SN 7-T MR 
images.
In PD patients, the macroscopic 
pallor of the SN pars compacta is be-
cause of the loss of pigmented neurons.
We argue that the hyperintense 
signal, visible in the intermediate tier 
of the SN in healthy subjects, disap-
peared in PD patients because of either 
the loss of melanized neurons and/or 
the increase of iron deposition, which 
would increase magnetic susceptibility 
and decrease signal intensity.
Three-dimensional multiecho sus-
ceptibility-weighted imaging is a T2*-
sensitive sequence in which signal 
hypointensity may reflect iron accumu-
lation that is considered a PD-related 
change (1,9,36) that occurs in SN pars 
compacta. In PD patients, the iron de-
posits in SN pars compacta reach the 
level of that in SN pars reticulata, where 
the iron content is normally twice than 
in SN pars compacta (37).
that show the loss of the three-layer or-
ganization and the lateral spot of the 
SN in PD patients. Those signs allowed 
us to discriminate with near-perfect ac-
curacy PD subjects from age-matched 
healthy subjects, which demonstrated a 
good diagnostic power of 7-T MR imag-
ing in PD.
According to previous pathologic 
studies (1,31), the SN is a midbrain 
structure that is anatomically divided 
into two distinct parts: the inferior and 
posterior part (SN pars compacta) that 
contain melanized neurons that project 
to the striatum and the superior and an-
terior part (SN pars reticulata), which 
is low in cells and rich in iron. The in-
ternal anatomy of the SN has been dif-
ferently classified on the basis of the 
distribution of neurons (1,32–34). Ac-
cording to a classic scheme (1) within 
the SN pars compacta, two tiers of pig-
mented neurons are identified, namely 
the dorsal (SN pars compacta dorsalis) 
and ventral (SN pars compacta ventra-
lis) tiers oriented anteromedially along 
the course of the mesencephalon. The 
anterior and posterior tiers can be 
further subdivided by using calbindin 
immunohistochemistry, which reveals 
zones that are low in calbindin, called 
nigrosomes, where pigmented neurons 
reside (33) and PD-related degenera-
tion begins (34).
In our study, 7-T MR targeted im-
ages of the midbrain provided a refined 
depiction of SN internal organization, 
which allowed for the identification of 
three tiers of different signal intensity 




Healthy Subjects PD Patients 
Level I Level II Level III Level I Level II Level III
Side R L R L R L R L R L R L
Reader 1 0 0 0 0 0 0 17 15 17 15 6 6
Reader 2 1 1 0 0 0 0 17 15 17 15 6 7
Note.—There were 13 healthy subjects and 17 PD patients. The subject was considered affected if one of the following criteria 
was detectable at least at one level (out of three) of one side (right or left) of the SN. Level I: loss of the hyperintense lateral spot 
of SN. Level II: loss of the three layers organization of SN. Level III: hypointensity represented both in the medial and lateral part 
of SN. L = left, R = right.
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